Jazz Pharmaceuticals (JAZZ) EBIAT: 2009-2025
Historic EBIAT for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $251.4 million.
- Jazz Pharmaceuticals' EBIAT rose 16.91% to $251.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $565.0 million, marking a year-over-year increase of 22.00%. This contributed to the annual value of $560.1 million for FY2024, which is 35.02% up from last year.
- According to the latest figures from Q3 2025, Jazz Pharmaceuticals' EBIAT is $251.4 million, which was up 371.68% from -$92.5 million recorded in Q2 2025.
- Jazz Pharmaceuticals' EBIAT's 5-year high stood at $251.4 million during Q3 2025, with a 5-year trough of -$363.3 million in Q2 2021.
- Over the past 3 years, Jazz Pharmaceuticals' median EBIAT value was $125.6 million (recorded in 2023), while the average stood at $113.4 million.
- Per our database at Business Quant, Jazz Pharmaceuticals' EBIAT crashed by 580.95% in 2022 and then skyrocketed by 4,114.94% in 2023.
- Over the past 5 years, Jazz Pharmaceuticals' EBIAT (Quarterly) stood at -$35.4 million in 2021, then plummeted by 580.95% to -$240.7 million in 2022, then surged by 139.11% to $94.2 million in 2023, then spiked by 102.98% to $191.1 million in 2024, then climbed by 16.91% to $251.4 million in 2025.
- Its EBIAT was $251.4 million in Q3 2025, compared to -$92.5 million in Q2 2025 and $191.1 million in Q4 2024.